In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
Axcelead’s Next CEO Eyes Sales of 120 Billion Yen, Ramp-Up in Mega Pharma Orders
To read the full story
Related Article
- Axcelead DDP Looks to Lift Overseas Sales Ratio to 80%: President
January 31, 2024
BUSINESS
- EA Pharma Grants Global Rights to IBD Drugs to Ensho
July 1, 2024
- Pfizer, Viatris to Copromote Cibinqo, Litfulo in Japan
July 1, 2024
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
- Eisai’s Alzheimer’s Med Leqembi Now Available in China
July 1, 2024
- Pfizer Seeks Japan Approval for Ulcerative Colitis Drug
July 1, 2024
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…